Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.

Aus, G; Damber, J; Khatami, A; Lilja, H; Stranne, J; Hugosson, J

Journal article

Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study.

Abstract:: BACKGROUND: The aim of the present study was to evaluate the future cumulative risk of prostate cancer in relation to levels of prostate-specific antigen (PSA) in blood and to determine whether this information could be used to individualize the PSA testing interval. METHODS: The study included 5855 of 9972 men (aged 50-66 years) who accepted an invitation to participate in a prospective, randomized study of early detection for prostate cancer. We used a protocol based on biennial PSA measurements starting from 1995 and 1996. Men with serum PSA levels of 3.0 ng/mL or more were offered prostate biopsies. RESULTS: Among the 5855 men, 539 cases of prostate cancer (9.2%) were detected after a median follow-up of 7.6 years (up to July 1, 2003). Cancer detection rates during the follow-up period in relation to PSA levels were as follows: 0 to 0.49 ng/mL, 0% (0/958); 0.50 to 0.99 ng/mL, 0.9% (17/1992); 1.00 to 1.49 ng/mL, 4.7% (54/1138); 1.50 to 1.99 ng/mL, 12.3% (70/571); 2.00 to 2.49 ng/mL, 21.4% (67/313); 2.50 to 2.99 ng/mL, 25.2% (56/222); 3.00 to 3.99 ng/mL, 33.3% (89/267); 4.00 to 6.99 ng/mL, 38.9% (103/265); 7.00 to 9.99 ng/mL, 50.0% (30/60); and for men with an initial PSA of 10.00 ng/mL or higher, 76.8% (53/69). Not a single case of prostate cancer was detected within 3 years in 2950 men (50.4% of the screened population) with an initial PSA level less than 1 ng/mL. CONCLUSIONS: Retesting intervals should be individualized on the basis of the PSA level, and the large group of men with PSA levels of less than 1 ng/mL can safely be scheduled for a 3-year testing interval.

Actions

Email

Email this record

Send the bibliographic details of this record to your email address.

Your Email
Please enter the email address that the record information will be sent to.

-
Your message (optional)
Please add any additional information to be included within the email.
Cite

Cite this record

APA Style

Aus, G., Damber, J., Khatami, A., Lilja, H., Stranne, J., & Hugosson, J. (2005). Individualized screening interval for prostate cancer based on prostate-specific antigen level: results of a prospective, randomized, population-based study. Archives of Internal Medicine, 165(16), 1857–1861.

MLA Style

Aus, G., et al. “Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level: Results of a Prospective, Randomized, Population-Based Study.” Archives of Internal Medicine, vol. 165, no. 16, 2005, pp. 1857–61.

Chicago Style

Aus, G, J Damber, A Khatami, H Lilja, J Stranne, and J Hugosson. 2005. “Individualized Screening Interval for Prostate Cancer Based on Prostate-Specific Antigen Level: Results of a Prospective, Randomized, Population-Based Study.” Archives of Internal Medicine 165 (16): 1857–61.
Share
Print